{
    "nct_id": "NCT03706040",
    "official_title": "A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Risankizumab in Adult and Adolescent Subjects With Moderate to Severe Atopic Dermatitis",
    "inclusion_criteria": "* adults who are â‰¥ 18 years old and, where locally permissible and approved, adolescent subjects who are at least 12 years old\n* a diagnosis of atopic dermatitis (AD) with onset of symptoms at least 2 years prior to Baseline and subject meets Hanifin and Rajka criteria\n* moderate to severe AD at the Baseline Visit\n* history of inadequate response to previous topical corticosteroid and/or topical calcineurin inhibitor treatments or a medical inability to receive these treatments\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* prior exposure to any biologic immunomodulatory agent or Janus kinase (JAK) inhibitor\n* concurrent treatment with systemic therapy for AD (biologic or non-biologic) or topical and/or phototherapy treatments",
    "miscellaneous_criteria": ""
}